CBER Topsider Initiatives Include Role In Device Meetings, Review Templates
This article was originally published in The Gray Sheet
Executive Summary
The Center for Biologics Evaluation & Research is pledging regular top-level participation in medical device meetings as part of a series of management initiatives for 2004
You may also be interested in...
Device Review Templates Are Milestones On Road To “Critical Path” – CBER
The Center for Biologics Evaluation & Research is flagging areas of the device review process that can be clarified through "templates" to guide staff and sponsors
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.